Faculty Opinions recommendation of A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
2013 ◽
Vol 31
◽
pp. 205-215
◽
2020 ◽
Vol 18
(2)
◽
pp. 236-243
2007 ◽
Vol 3
(01)
◽
2019 ◽
Vol 176
(5)
◽
pp. 401-409
◽